Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Rising temperatures may increase the severity of obstructive sleep apnea (OSA), according to a large new study presented at ...

Patients with sleep apnea receiving pulmonary rehabilitation had 34% lower all-cause mortality than similar patients who did not receive PR.

Rising temperatures may make sleep apnea worse, researchers say. Editor at Large We all have cause to take climate change ...

Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy ...

A wearable pulse oximeter and connected software platform show promise for monitoring obstructive sleep apnea (OSA) and other sleep-related breathing diseases, according to research presented at the ...

A new study presented at ATS 2025 reveals that rising temperatures significantly worsen obstructive sleep apnea severity, ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

Medical cannabis has improved sleep for Minnesotans who suffer from obstructive sleep apnea, according to a new study from the state Office of Cannabis Management (OCM). The study, released ...

Preliminary screening for OSA in children who are awake, performed via an EEG, may help identify whether oxygen desaturation occurs at night.